Titan Pharmaceuticals, Inc. – NASDAQ:TTNP
Titan Pharmaceuticals stock price today
Titan Pharmaceuticals stock price monthly change
Titan Pharmaceuticals stock price quarterly change
Titan Pharmaceuticals stock price yearly change
Titan Pharmaceuticals key metrics
Market Cap | 3.00M |
Enterprise value | N/A |
P/E | -1.04 |
EV/Sales | -7.90 |
EV/EBITDA | 0.36 |
Price/Sales | 0.03 |
Price/Book | N/A |
PEG ratio | -0.06 |
EPS | -6.32 |
Revenue | N/A |
EBITDA | -8.30M |
Income | -4.95M |
Revenue Q/Q | -100% |
Revenue Y/Y | -71.61% |
Profit margin | -2206.75% |
Oper. margin | -2202.14% |
Gross margin | 99.84% |
EBIT margin | -2202.14% |
EBITDA margin | N/A |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeTitan Pharmaceuticals stock price history
Titan Pharmaceuticals stock forecast
Titan Pharmaceuticals financial statements
| Jun 2023 | 1K | -1.58M | -158600% |
|---|---|---|---|
| Sep 2023 | 4K | -338K | -8450% |
| Dec 2023 | 81K | -1.97M | -2432.1% |
| Mar 2024 | 0 | -1.06M |
| 2025 | 7.05M | -6.46M | -91.72% |
|---|---|---|---|
| 2026 | 35.35M | 13.08M | 37.01% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 812000 | 1.84M | 227.34% |
|---|---|---|---|
| Sep 2023 | 9999000 | 1.86M | 18.66% |
| Dec 2023 | 8086000 | 1.44M | 17.86% |
| Mar 2024 | 6646000 | 559K | 8.41% |
| Jun 2023 | -1.11M | 0 | 0 |
|---|---|---|---|
| Sep 2023 | -1.83M | 228K | 9.59M |
| Dec 2023 | -2.24M | 504K | 406K |
| Mar 2024 | -613K | 0 | 0 |
Titan Pharmaceuticals alternative data
| Aug 2023 | 4 |
|---|---|
| Sep 2023 | 4 |
| Oct 2023 | 4 |
| Nov 2023 | 4 |
| Dec 2023 | 4 |
| Jan 2024 | 4 |
| Feb 2024 | 4 |
| Mar 2024 | 4 |
| Apr 2024 | 4 |
| May 2024 | 4 |
| Jun 2024 | 4 |
| Jul 2024 | 4 |
Titan Pharmaceuticals other data
| Period | Buy | Sel |
|---|---|---|
| Jul 2022 | 2226190 | 0 |
| Jan 2023 | 57500 | 0 |
| Jun 2023 | 0 | 718132 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | LAZAR DAVID E. director, 10 percent owner, off.. | Common Stock, par value $0.001 | 718,132 | $1.23 | $883,302 | ||
Purchase | LAZAR DAVID E. officer: Chief Executive Officer | Common Stock, par value $0.001 | 20,000 | $1 | $20,060 | ||
Purchase | LAZAR DAVID E. director, 10 percent owner, off.. | Common Stock, par value $0.001 | 37,500 | $0.97 | $36,225 | ||
Purchase | LAZAR DAVID E. 10 percent owner | Common Stock, par value $0.001 | 744,294 | $0.99 | $739,084 | ||
Purchase | LAZAR DAVID E. 10 percent owner | Common Stock, par value $0.001 | 315,921 | $0.89 | $282,117 | ||
Purchase | LAZAR DAVID E. 10 percent owner | Common Stock, par value $0.001 | 1,165,975 | $0.77 | $902,465 | ||
Purchase | RECLI FEDERICO SEGHI director | Common Stock | 200,000 | N/A | N/A | ||
Purchase | RECLI FEDERICO SEGHI director | Common Stock | 500,000 | N/A | N/A | ||
Purchase | BHONSLE SUNIL director, officer: President an.. | Common Stock | 300,000 | N/A | N/A | ||
Purchase | RUBIN MARC director, officer.. | Common Stock | 400,000 | N/A | N/A |
| Patent |
|---|
Application Filling date: 10 Sep 2021 Issue date: 4 Aug 2022 |
Application Filling date: 25 Jun 2019 Issue date: 17 Jun 2021 |
Application Filling date: 25 Jun 2019 Issue date: 22 Apr 2021 |
Application Filling date: 16 Mar 2020 Issue date: 18 Feb 2021 |
Application Filling date: 5 Oct 2017 Issue date: 14 Jan 2021 |
Application Filling date: 17 Dec 2018 Issue date: 21 Nov 2019 |
| Quarter | Transcript |
|---|---|
| Q3 2020 16 Nov 2020 | Q3 2020 Earnings Call Transcript |
| Q2 2020 14 Aug 2020 | Q2 2020 Earnings Call Transcript |
| Q1 2020 15 May 2020 | Q1 2020 Earnings Call Transcript |
| Q4 2019 30 Mar 2020 | Q4 2019 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Dr. Katherine L. Beebe-DeVarney Ph.D. (1961) Pres, Chief Operating Officer & Director | $365,000 |
| Dr. Marc Rubin M.D. (1955) Executive Chairman & Principal Executive Officer | $250,520 |
-
What's the price of Titan Pharmaceuticals stock today?
One share of Titan Pharmaceuticals stock can currently be purchased for approximately $5.06.
-
When is Titan Pharmaceuticals's next earnings date?
Unfortunately, Titan Pharmaceuticals's (TTNP) next earnings date is currently unknown.
-
Does Titan Pharmaceuticals pay dividends?
No, Titan Pharmaceuticals does not pay dividends.
-
How much money does Titan Pharmaceuticals make?
Titan Pharmaceuticals has a market capitalization of 3.00M and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 206.67% to 184K US dollars.
-
What is Titan Pharmaceuticals's stock symbol?
Titan Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "TTNP".
-
What is Titan Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Titan Pharmaceuticals?
Shares of Titan Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Titan Pharmaceuticals's key executives?
Titan Pharmaceuticals's management team includes the following people:
- Dr. Katherine L. Beebe-DeVarney Ph.D. Pres, Chief Operating Officer & Director(age: 64, pay: $365,000)
- Dr. Marc Rubin M.D. Executive Chairman & Principal Executive Officer(age: 70, pay: $250,520)
-
How many employees does Titan Pharmaceuticals have?
As Jul 2024, Titan Pharmaceuticals employs 4 workers.
-
When Titan Pharmaceuticals went public?
Titan Pharmaceuticals, Inc. is publicly traded company for more then 29 years since IPO on 18 Jan 1996.
-
What is Titan Pharmaceuticals's official website?
The official website for Titan Pharmaceuticals is titanpharm.com.
-
Where are Titan Pharmaceuticals's headquarters?
Titan Pharmaceuticals is headquartered at 400 Oyster Point Boulevard, South San Francisco, CA.
-
How can i contact Titan Pharmaceuticals?
Titan Pharmaceuticals's mailing address is 400 Oyster Point Boulevard, South San Francisco, CA and company can be reached via phone at +65 02444990.
Titan Pharmaceuticals company profile:
Titan Pharmaceuticals, Inc.
titanpharm.comNASDAQ
4
Biotechnology
Healthcare
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program (TP-2021) for use in combination with ProNeura technology for the treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.
South San Francisco, CA 94080-1958
CIK: 0000910267
ISIN: US8883147055
CUSIP: 888314606
